Orchestra BioMed Holdings, Inc. (OBIO)

NASDAQ: OBIO · IEX Real-Time Price · USD
-0.43 (-2.74%)
At close: Mar 29, 2023, 4:00 PM
-0.31 (-2.03%)
After-hours: Mar 29, 2023, 5:10 PM EDT
Market Cap 36.81M
Revenue (ttm) 1.65M
Net Income (ttm) -48.59M
Shares Out 2.41M
EPS (ttm) -21.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,220
Open 15.72
Previous Close 15.69
Day's Range 14.06 - 15.72
52-Week Range 7.49 - 19.18
Beta n/a
Analysts Buy
Price Target 19.04 (+24.77%)
Earnings Date Jan 25, 2023

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 45
Stock Exchange NASDAQ
Ticker Symbol OBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $19.04, which is an increase of 24.77% from the latest price.

Price Target
(24.77% upside)
Analyst Consensus: Buy
Stock Forecasts


Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

1 month ago - GlobeNewsWire

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023

2 months ago - GlobeNewsWire

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients

9 months ago - GlobeNewsWire